retatrutide
Selected indexed studies
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. (N Engl J Med, 2023) [PMID:37366315]
- Retatrutide-A Game Changer in Obesity Pharmacotherapy. (Biomolecules, 2025) [PMID:40563436]
- The power of three: Retatrutide's role in modern obesity and diabetes therapy. (Eur J Pharmacol, 2024) [PMID:39515565]
_Worker-drafted node — pending editorial review._
Connections
retatrutide is a side effect of
Sources
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. (2023) pubmed
- Retatrutide-A Game Changer in Obesity Pharmacotherapy. (2025) pubmed
- The power of three: Retatrutide's role in modern obesity and diabetes therapy. (2024) pubmed
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. (2023) pubmed
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. (2024) pubmed
- Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. (2024) pubmed
- Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. (2026) pubmed
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. (2025) pubmed
- Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials. (2025) pubmed
- Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. (2025) pubmed